GlassScriptPhysician profile
Marvin M Singh
NPI 1306968417
$10,699.01
in general payments reported to CMS, 2019-2025
27 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,348 · 2020: $2,596 · 2021: $2,584 · 2022: $91.29 · 2023: $544 · 2024: $1,129 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539 · Long Term Medical Supply Or Device Loan: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.70 |
| Long Term Medical Supply Or Device Loan | $542.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,664.60 | 2019-2024 | Xifaxan, Trulance |
| Concordia Pharmaceuticals INC. | $2,264.87 | 2019 | |
| Wilson Cook Medical Incorporated | $2,225.00 | 2021 | |
| Abbvie INC. | $858.71 | 2019-2024 | Rinvoq, Skyrizi, Creon |
| Parapro, LLC | $600.00 | 2019 | |
| Pentax of America, INC. | $552.35 | 2024 | Video Colonoscope, Pentax Medical, C2 Cryoballoon Focal Controller |
| Janssen Biotech, INC. | $253.31 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $234.00 | 2019-2024 | Entyvio, Gattex |
| Pfizer INC. | $176.94 | 2019-2025 | |
| Lilly USA, LLC | $176.26 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $123.25 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $83.31 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $69.48 | 2024 | |
| Intercept Pharmaceuticals, INC. | $62.95 | 2020-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $56.59 | 2019-2023 | Rebyota |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $45.00 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $38.04 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $32.22 | 2023 | Zeposia |
| Amgen INC. | $28.54 | 2021 | |
| Thd America, INC. | $23.17 | 2025 | |
| Amag Pharmaceuticals, INC. | $22.62 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $21.47 | 2023 | Fujifilm |
| Sandoz INC. | $21.15 | 2024 | Hyrimoz |
| Ucb, INC. | $18.40 | 2019 | |
| Merck Sharp & Dohme LLC | $18.36 | 2024 | Dificid |
| Qol Medical, LLC | $14.30 | 2019 | |
| Aimmune Therapeutics, INC. | $14.12 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.